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1. Introduction 
The inflammatory cascade in acute bacterial meningitis leads to tissue damage and exudates 
accumulation especially in H. influenza, pneumococcal meningitis and in tuberculous 
meningitis. The administered antibiotics will also exaggerate the formation of inflammatory 
exudates from tissue destruction and endotoxins from bacterial lysis, resulting in edema 
formation. Accumulation of these inflammatory substrates, neutrophils and edema 
ultimately results in ischemia and pressure effect on neurons and nerve fibers with 
worsening of neurological signs and symptoms.  
Despite the effective antibiotic therapies, bacterial meningitis still has considerable 
morbidity and mortality in both adult and pediatric population. (Brouwer MC et al., 2010). 
Other than the definitive treatment with appropriate antibiotics, supportive and adjuvant 
therapy has its own characteristic role in the improved outcome of disease. Evidence from 
experimental models also support the role of adjuvant therapy like, early administration of 
glucocorticoids in selective cases of pyogenic meningitis, however most modalities 
investigated so far have not been sufficiently supportive for their routine use in the 
management of all cases of meningitis.  
2. Pathophysiology 
According to Monro-Kellie doctrine (Morki B, 2008), if there is an increasing size of one 
constituent or a mass within the cranial vault, the pressure will be shared by either brain, 
arterial and venous blood flow and/or the CSF. Similarly, if there is trauma or inflammation 
to brain parenchyma or meninges, exudates will accumulate with oedema, and edematous 
and inflamed brain causes either partial or complete obstruction of CSF flow which may 
results in hydrocephalus. Edematous and inflamed brain reduces the venous blood flow 
from cranial vault, leading to venous congestion and edema, on the other hand, it  also 
hampered arterial blood supply and hence reduce brain perfusion, and oxygenation which 
may further aggravate hypoxic inflammation and hence worsening of edema, thereby 
further increasing intra cranial venous congestion and pressure, consequently 
compromising the brain parenchyma results in different clinical presentation like altered 
mental status.   
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Fig. 1. Monro-Kellie hypothesis: Increase in volume (mass effect) of cranial constituents 
(blood, CSF, and brain tissue) must be compensated by a decrease in volume of another.  
 
Fig. 2. Monro-Kellie hypothesis in case of increase intracranial pressure and hydrocephalus, 
compromising arterial and venous blood and compressed brain parenchyma and CSF.  
3. Role of anti inflammatory agents 
There are wide spectrum of complications associated with meningitis, these may be 
neurological and non neurological (systemic). Systemic complications relate with bacteremia 
and related toxins, which ranges from sepsis to septic shock, disseminated intravascular 
coagulation, respiratory distress syndrome and respiratory arrest, while prolong fever, 
vasomotor collapse, pericardial effusion, arthritis, hypothalamic and other endocrine 
dysfunction including hyponatremia and bilateral adrenal hemorrhage are also not 
uncommon. Anemia may also manifest as a part of meningitis. 
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Several anti inflammatory agents have been studied in reducing the inflammatory exudates 
in animal model of pyogenic and other type of meningitis. Indomethacin, platelet factor 
inhibitors and pentoxifylline, recombinant protein C, intravenous immunoglobulin and 
monoclonal antibodies, have been evaluated for their isolated and combine anti 
inflammatory properties in reducing the CSF inflammation and edema, but none of them 
have evident promising results. (Singhi P et al., 2008)  
Though the role of glucocorticoids in systemic complications of meningitis is not discussed 
in the literature as extensively as it has been described for neurological outcomes, especially 
in reducing the incidence of hearing loss and other acute or chronic neurological sequel, on 
the contrary, use of glucocorticoids did not reduce overall mortality in most cases of 
meningitis. Cochrane review data supports its use in patients with bacterial meningitis in 
high-income countries, but results were not found to be beneficial from low-income 
countries. (Daoud AS et al., 1999). Bacterial immunogenicity, host immunity and response, 
timing and efficacy of antibiotics and steroids used and susceptibility of organism all 
account for the consequences in low income countries. The adjunctive benefit of 
corticosteroids during treatment of meningitis caused by other organisms (viral, fungal, and 
parasitic) is unknown. 
4. Role of steroids in meningitis 
With its unique anti-inflammatory and immune suppressive properties, efficacy of this drug 
has been extensively studied in different types of meningitis. Adjuvant therapy of 
glucocorticoids like dexamethasone is useful in both adult and pediatric meningitis and 
tuberculous meningitis as evident from experimental studies and vast growing clinical data. 
(Friedland IR et al., 1994). 
Steroid limits the production of inflammatory mediators like IL-1, IL-6 and TNF and 
exudates and help in reduction of edema, resulting in the decrease cerebral pressure and 
hence improve CSF flow within the cistern thus helps in stabilizing the blood brain barrier 
(BBB), this in turn leads to improvement of neurological symptoms. (Karen & Tyler 2008). 
Dexamethasone also inhibits the production of TNF by macrophages and microglia, but 
only if it is administered before these cells are activated by endotoxin. 
A meta-analysis conducted in 2010 on the role of dexamethasone in pediatric meningitis has 
shown that dexamethasone did not improve overall mortality; however it can reduces 
severe hearing loss in children. (Brouwer MC et al., 2010). However, the etiological agents, 
nutritional status, prior immunity and immunization and demography play an important 
role in outcome of such meningitis.  
Most experts had consensus on the beneficial role of steroid with its maximum benefits 
when it is used at least one hour prior to recommended antibiotics therapy. (King, 1994: 
Pickering, 2009). Regarding H. Influenzae meningitis in children older than six week age, 
the use of steroid prior to antibiotics is recommended by American Academy of Pediatrics 
and as describe Infectious Diseases Society of America (IDSA) guidelines 2004. (Tunkel AR 
et al., 2004). In H. Influenzae meningitis steroids significantly reduce the risk of 
sensorineural hearing loss, while other experts’ belief that outcome of meningitis is not 
dependent on steroids when it was given. Dexamethasone also did not help in ameliorating 
the other neurologic consequences especially in children. (Brouwer MC et al., 2010). 
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Beneficial role of dexamethasone in neonatal meningitis has not been evidence from the 
literature. It is not indicated in bacterial meningitis in children younger than six weeks as it 
does not shown promising results in different past studies. Steroids are also not advised as 
adjuvant therapy in patients with congenital or acquired CNS anomalies. (Daoud AS et al., 
1999). 
The severity of illness at the time of presentation may appear to play a prominent role in 
outcome than just administration of adjuvant therapy with dexamethasone. (Peltola H et al., 
2010). On the other hand dexamethasone may also mask the clinical presentation of 
meningitis, or any of its associated sequels like abscess, empyema, subdural collection, 
tuberculous meningitis, resistant meningitis. Routine administration of dexamethasone is also 
not recommended in developing countries as most patients got their first few doses of 
antibiotics before the diagnosis of meningitis. Still dexamethasone has a role in reducing the 
inflammatory exudates if given with or given soon after the initial antibiotics preferably within 
one hour, but this time interval is not clearly defined in literature. (King SM et al., 1994).  
With the advent of effective immunization against H. Influenzae globally, Streptococcal 
Pneumoniae is becoming the common organism causing meningitis. Resistant of S. 
pneumonia to cephalosphorins group is also evidently increasing from literature. 
Widespread use of susceptible vancomycin against these resistant species of S. pneumonae 
is increasing. At the same time studies had shown an increasing number of therapeutic 
failures when dexamethasone is combine with vancomycin and various other antibiotics like 
rifampicin and cephalosporin etc. steroids may reduce the penetration of these antibiotics in 
CSF or it may lead to decrease level of some antibiotic (eg, vancomycin, ceftriaxone, and 
rifampin) within the CSF, mechanism is not clear. (Friedland, 1994: Moellering, 1984). 
  
Fig. 3. CT scan brain showing low attenuated areas and increase enhancements with 
hydrocephalus in patient with pneumococcal meningitis 
www.intechopen.com
 
Role of Dexamethasone in Meningitis 213 
Dexamethasone in case of pneumococcal meningitis should be use after considering the 
risks and benefits. In adults with pneumococcal meningitis; dexamethasone has shown to 
have clinical benefits in term of neurological outcomes, but in children its use is 
controversial in pneumococcal meningitis. On the other hand few experts recommend that it 
should be used in all cases of confirm or suspected pneumococcal meningitis even if they 
are previously vaccinated, while other focused on the risk and benefits. However experts’ 
consensus that steroid is only effective in reducing hearing loss if given before antibiotics. 
(Pickering 2009). 
In patients with hypo spleenism, sickle cell disease and complement and immune 
deficiency, corticosteroids should be use cautiously. Thus controversies for its use in 
pneumococcal meningitis still persist. Dexamethasone is also not recommended in patients 
with aseptic meningitis, nonbacterial, or meningitis with gram-negative enteric bacteria. In 
such cases dexamethasone if started before should be discontinued as soon as a diagnosis of 
nonbacterial or gram-negative enteric meningitis is confirmed. (Tunkel AR et al., 2004). 
Randomized controlled trials from low income country with steroid therapy in tuberculosis 
meningitis for initial 6-8 weeks of anti tubercular treatment were found to have significantly 
reduced mortality in patients who present with stage I disease; there was also reduce 
mortality noticed in patients who present with stage II disease. (Thwaites, GE. et al., 2008). 
However there was no significant long term reduction in the residual neurologic deficits 
and disability among survivors. Prednisone as compare to dexamethasone is associated with 
a significant reduction in mortality in children with tuberculous meningitis as compare to 
adults. (Thwaites, GE. et al., 2008). 
5. Doses of dexamethasone in meningitis  
In case of pyogenic meningitis dexamethasone should be used at 0.15 mg/kg per dose 
(10 mg intravenously in adults) every six hours for two to four days (Tunkel AR et al., 2004). 
Two days of dexamethasone appear to be as effective as and less toxic than longer courses. 
(Syrogiannopolus GA et al., 1994) 
Steroids should be started at presentation or before or with the commencement of anti 
tubercular therapy. Dexamethasone, dose of 8 mg/day for children weighing <25 kg, 12 
mg/day for adults and children >25 kg, for 3 weeks, and then tapered off gradually over the 
following 3 to 4 weeks. Prednisone, dose of 2 to 4 mg/kg/day for children and 60 mg/day 
for adults, for 3 weeks, then tapered off gradually over the following 3 weeks. 
6. Complication of dexamethasone 
Problems related with the glucocorticoids use are usually associated with it prolong 
duration. There may be complexity in clinical assessment and response to therapy, 
gastrointestinal bleeding, secondary fever, hypertension, hyperglycemia, leukocytosis etc. It 
may also impair antibiotic penetration into the cerebrospinal fluid (CSF) that can lead to 
therapeutic failure, particularly in areas with increasing rates of penicillin-resistant S. 
pneumonia. (Thomas R et al., 1999). 
Corticosteroids do not reverse CNS damage that has already resulted from the 
pathophysiologic consequences of bacterial meningitis (e.g., cerebral edema and increased 
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intracranial pressure). However, even in children with bacterial meningitis in the 
developing world, use of adjunctive dexamethasone should be considered, because no 
adverse effects were attributable to its administration in this trial and its use may benefit 
some of the children with this devastating disorder. (Mongelluzo J et al., 2008)  
7. Dexamethasone in adult meningitis  
Clinical trials of corticosteroids (dexamethasone) as adjuvant therapy have been conducted 
in different centers all over the world with inconsistent results. However studies shown that 
corticosteroids significantly reduced severe hearing loss and other neurologic sequel, while 
on other hand, it is also helpful in reducing the overall mortality. Meta analysis using 
dexamethasone in adult meningitis demonstrates favorable outcomes in terms of both 
morbidity and mortality especially in cases of pneumococcal meningitis. It also reduces 
mortality in adult onset streptococcal pneumonae meningitis. (Daniel J S et al., 2010). 
Dexamethasone is also associated with reduce rate of acute neurological and hearing defect, 
however there was no difference in long term neurological sequelae, (Brouwer MC et al., 
2010) although some experts recommend to discontinue dexamethasone if S. pneumonia 
was not found in the CSF culture, but others still recommend the use of adjunctive 
dexamethasone regardless of microbial etiology in conjunction with the first dose of 
antimicrobial therapy. (de Gans & Van de, 2002) 
8. Dexamethasone in pediatric meningitis  
The role of dexamethasone use in cases of pediatric meningitis is more controversial, it must 
be individualized according to the organism especially in case of H. influnzae and 
pneumococcal meningitis. Even though, a better outcome can only be attained if 
dexamethasone is use before or at the same time of first dose of antibiotics. (Tunkel AR et 
al., 2004). Routine use of dexamethasone in pediatric population is not recommended, 
potential risk and benefits must be taken in to account as it may not reverse neuronal 
damage that has already resulted from the pathophysiologic consequences of bacterial 
meningitis.  
However, even in children with bacterial meningitis in the developing world, use of 
adjunctive dexamethasone should be considered, because no adverse effects were 
attributable to its administration in different trials and its use may benefit some of the 
children with this devastating disorder. 
9. Dexamethasone in neonatal meningitis 
The administration of dexamethasone did not significantly affect mortality or neurologic 
outcome in small children up to two years of age, hence it is not currently recommended. 
(Daoud AS et al., 1999). 
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